Analyst Coverage Sparks Interest in These 4 Stocks Amid VolatilityZacks Investment Research • 07/25/25
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)GlobeNewsWire • 07/09/25
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 12/16/24
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 10/09/24
KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 08/23/24
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/24
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?Zacks Investment Research • 04/04/24
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/29/24
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/23
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/04/23
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/19/23
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/23
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCEDGlobeNewsWire • 04/28/23
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCEDGlobeNewsWire • 03/27/23